Davalintide 是一种 Amylin (MS-V92302) 模拟肽,具有强效力和更长效的作用,是胰淀素受体 (amylin receptor) (IC50 = 0.04 nM)、降钙素受体 (calcitonin receptor) (IC50 = 0.06 nM) 以及降钙素相关肽受体 (CGRP receptor) (IC50 = 3.1 nM) 的高效激动剂,在通过降钙素受体激活环磷酸腺苷生成方面比 Amylin 具有更强效力 (EC50 = 1.4 nM),并通过延缓胃排空、抑制胰高血糖素分泌以及减少食物摄入等多种机制调节血糖和体重,可用于抗肥胖和抗糖尿病的研究。
产品编号: MS-E63123 纯度: 98.04% CAS No.: 863919-85-1 分子式: C152H248N50O49S2 分子量: 3624.03
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Davalintide 是一种 Amylin (MS-V92302) 模拟肽,具有强效力和更长效的作用,是胰淀素受体 (amylin receptor) (IC50 = 0.04 nM)、降钙素受体 (calcitonin receptor) (IC50 = 0.06 nM) 以及降钙素相关肽受体 (CGRP receptor) (IC50 = 3.1 nM) 的高效激动剂,在通过降钙素受体激活环磷酸腺苷生成方面比 Amylin 具有更强效力 (EC50 = 1.4 nM),并通过延缓胃排空、抑制胰高血糖素分泌以及减少食物摄入等多种机制调节血糖和体重,可用于抗肥胖和抗糖尿病的研究。

生物实验数据

生物活性 Davalintide is an Amylin (MS-V92302) mimetic peptide with potent and longer-acting effects, acting as a highly potent agonist of the amylin receptor (IC50 = 0.04 nM), the calcitonin receptor (IC50 = 0.06 nM), and the CGRP receptor (IC50 = 3.1 nM), displaying greater potency than Amylin in activating cyclic AMP production via the calcitonin receptor (EC50 = 1.4 nM), and regulating blood glucose and body weight through multiple mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake, making it useful for anti-obesity and anti-diabetic research.
体内研究
(In Vivo)

Davalintide (1.09-1087 μg/kg (小鼠);5 μg/kg (大鼠),腹腔注射,单剂量) 可抑制禁食小鼠和过量喂养大鼠的食物摄入,其疗效和作用持续时间均优于 Amylin。
Davalintide (1-100 μg/kg,腹腔注射,单剂量) 在减少大鼠食物摄入量时不影响其自主活动,其对食欲的抑制作用并非由恶心或厌恶等不良反应介导。
Davalintide (1-100 μg/kg,皮下注射,每日一次,持续输注 8 周) 可有效减少大鼠的食物摄入量和体重,其减重主要体现在脂肪减少上,同时保持瘦体重,其代谢益处远不止简单的限制食物摄入量。
Davalintide (10 μg/kg,皮下注射,每日一次,持续输注4周) 显著降低大鼠总热量摄入,降低对高脂肪和美味食物的偏好,并促使大鼠选择标准饲料。
Davalintide (10 μg/kg,腹腔注射,单次给药) 作用于脑干后级区,通过更持久地激活大鼠的下游神经通路来达到抑制肥胖的效果。
Davalintide (10 μg/kg,皮下注射,单次给药) 显著抑制麻醉大鼠精氨酸刺激引起的胰高血糖素升高,且对胰高血糖素的抑制作用具有特异性。

Animal Model: Acute food intake inhibition experiment established in fasted overnight NIH Swiss mice (24-30 g) and overfed Sprague-Dawley (SD) rats (weighing 394-461 g)
Dosage: 1.09-1087 μg/kg (mice); 5 μg/kg (rats)
Administration: Intraperitoneal injection (i.p.), single dose
Result: And Amylin both significantly and dose-dependently inhibited acute food intake (mice ED50: 87 μg/kg vs. Amylin 110 μg/kg)
Exhibited the duration of action significantly longer than that of Amylin (23 hours vs. 6 hours) in the experiment where obese rats were subjected to the dark cycle (the main feeding period).
Animal Model: Behavioral safety experiment established fasted Sprague-Dawley (SD) rats (weighing 325-425 g)
Dosage: 1, 10, 100 μg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Dose-dependently and persistently reduced food intake and body weight (8-week ED50 = 1.2 μg/kg/day).
Significantly reduced the level of plasma triglycerides.
Animal Model: Continuous infusion experiment (metabolic effect) established in obese rats induced by diet (Levin or SD rats, ~464 g), maintained on a 32% high-fat diet
Dosage: 1, 3, 10, 100 μg/kg
Administration: Subcutaneous injection (s.c.), once daily for 8 weeks
Result: Dose-dependently and persistently reduced food intake and body weight (8-week ED50 = 1.2 μg/kg/day).
Significantly reduced the level of plasma triglycerides.
Animal Model: Food preference experiment established in DIO rats (~ 515 g) provided with both standard feed and 32% high-fat feed for them to choose freely
Dosage: 10 μg/kg
Administration: Subcutaneous injection (s.c.), once daily for 4 weeks
Result: Significantly reduced total calorie intake.
Significantly reduced the preference for high-fat and delicious foods, and prompted the animals to choose standard feed.
Animal Model: Energy metabolism experiment established in SD rats (~ 421 g), maintained on a 32% high-fat diet for 5 weeks
Dosage: 30 μg/kg
Administration: Subcutaneous injection (s.c.), once daily for 4 weeks
Result: Exhibited the energy consumption (VO₂) of not different from that in the Vehicle group.
Slight but significant increased RQ values at the end of the second week.
Animal Model: Area postrema (AP) damage experiment established in SD rats (weighing 175-200 g) underwent AP lesion surgery or sham surgery, and the experiments were conducted several months after recovery
Dosage: 10 μg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Significantly reduced food intake in the sham operation group.
Completely eliminated the effect of suppressing appetite in the AP lesion group.
Animal Model: Neuronal activation (c-Fos expression) established in SD rats (400 g), maintained on a 32% high-fat diet
Dosage: 10 μg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Activated the same neural pathways to Amylin, but its effects lasted longer.
Animal Model: Glucagon inhibition experiment established in starved SD rats (250-280 g) and SD rats (350-370 g)
Dosage: 10 μg/kg
Administration: Subcutaneous injection (s.c.), single dose
Result: Significantly inhibited the glucagon secretion stimulated by arginine.
Was no difference in blood glucose and insulin levels during the clamp period.
性状 固体
颜色 White to light yellow

化学信息

分子量 3624.03
分子式 C152H248N50O49S2
CAS No. 863919-85-1

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 12.5 mg/mL (3.45 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.2759 mL1.3797 mL2.7594 mL6.8984 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础